Print

Print


**  Apologies for cross-posting  **



Please be advised of the following release from Thomson Reuters:

"Thomson Reuters releases comprehensive disease profile on Ebola Virus disease - 19 Aug 2014

The Intellectual Property and Science business of Thomson Reuters<http://ip-science.thomsonreuters.com/> has released a comprehensive disease profile on Ebola Virus Disease that includes a detailed analysis of two new treatments in the pipeline and two experimental candidates approaching development.

Ebola deaths in West Africa have exceeded the 1,000 mark since ravaging Liberia. Practitioners in Britain were recently ordered to look out for symptoms of the killer virus to stop it from taking hold in the UK, with doctors receiving new guidelines on how to deal with suspected cases. Ebola Virus Disease is particularly lethal. According to the World Health Organization, outbreaks have a fatality rate of up to 90 percent. There is currently no effective treatment.

The Thomson Reuters Ebola Disease Briefing is available free of charge through its LS Research website, a resource providing researchers with the latest news on disease insights and developing treatments, through reports and biological pathway maps. This resource offers disease profiling and comparative data to the current drug landscape for clinically devastating, relevant diseases, such as Ebola.

Through analysis using Thomson Reuters Integrity - an industry-leading resource providing researchers with reliable, detailed drug R&D information across multiple disciplines - LS Research analysts identified two potential Ebola treatments in the drug pipeline: Sarepta Therapeutics' VP24 expression inhibitor known as "AVI-7537" and Tekmira's VP24 expression inhibitor known as "Ebola SNALP."

VP24 is believed to play a significant role in Ebola Virus Disease, and may have an effect on the formation and replication of the viral genome. Scientists are now exploring the inhibition of this VP24 protein as a potential treatment to block the building and reproduction of the Ebola Virus genome. Both of these treatments are currently in Phase 1 clinical trials. The LS Research site also provides comprehensive information on the disease itself.

To further support the efforts in the fight against the Ebola virus, Thomson Reuters BioWorld, an industry-leading biopharmaceutical news resource, has comprised a collection of articles highlighting the most innovative research in recent years and the latest updates to provide greater insight into the disease and the treatments in development.

To view this special report visit Bioworld: http://www.bioworld.com/content/special-report-push-contain-ebola-virus

To read the full original press release: http://thomsonreuters.com/press-releases/082014/early-stage-ebola-treatments "

Kind Regards,
Lorna

~~~~~~~~~~~~

Mimas Web of Science Support

e: [log in to unmask]<mailto:[log in to unmask]>

w: http://wok.mimas.ac.uk